07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , May 23, 2005 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe Company Name Country Raised Investors Arpida Switzerland $67.4 Swissfirst; Temasek Capital; Carnegie Asset Management; CDIB BioScience Ventures; CITA; MVI Medical Venture Investments; Schroder Ventures Life Sciences; Alta Berkeley Associates; Aventic;...
08:00 , Mar 20, 2000 |  BioCentury  |  Finance

Waiting for the verdict

All eyes will be on Celltech as the London Stock Exchange opens for business on Monday, the first day it will trade as a FTSE 100 company. The LSE was closed when an FDA advisory...
08:00 , Jan 4, 2000 |  BC Week In Review  |  Company News

Tissuemed board of directors update

Tissuemed Ltd., Leeds, U.K.   Business: Biomaterial/Skin/Wound   Appointed: Laurie Rostron, former general partner at Alta Berkeley Associates, as a non-executive director   Resigned: Christopher Crabtree as a non-executive director   ...
07:00 , Sep 7, 1999 |  BioCentury  |  Finance

Just a little off the top, please

After jacking up as high as $19 intraday on Friday,CV Therapeutics (CVTX) finally slipped $1.375 to $18.125 on 483,300 shares on Friday on news of its plans to float a 4 million share follow-on, but...
07:00 , Oct 20, 1997 |  BioCentury  |  Finance

European private rounds

European private rounds Acadia Pharmaceuticals (formerly Receptor Technologies) $13.5M Danish subsidiary of San Diego high throughput screening company raises funds from Danish consortium including Dansk Kapitalanlog, BankInvest, Lonmodtagernes Dyrtidsfond and Kommuernes Pensionforsikring and Vokstfonden, Denmark's...
07:00 , Aug 11, 1997 |  BioCentury  |  Strategy

SmithKline spins out its orphan assets

Noteworthy There is a growing realization among the major pharmaceutical companies that even with billion-dollar R&D budgets there always will be research projects that cannot be provided with adequate resources. Moreover, the increasing pressure to...